HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
Press releases
September 14, 2021
BMG Pharma and HTL sign a development agreement
The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis.
– Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.
Read more below
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Press releases November 13, 2026HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
-
Articles October 30, 20262026 Regenerative Science Summit
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
-
Articles September 8, 2026HTL Biotechnology releases its 2025 CSR Report
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.